Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea
Supportive Care in Cancer, ISSN: 1433-7339, Vol: 25, Issue: 2, Page: 581-587
2017
- 1Citations
- 22Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations1
- Patent Family Citations1
- 1
- Captures22
- Readers22
- 22
Article Description
Purpose: The aim of this study was to test a new blood-based assay for its ability to predict delayed chemotherapy-induced nausea. Methods: Blood drawn from consented patients prior to receiving their first platinum-based therapy was tested for glutathione recycling capacity and normalized to total red cell numbers. This number was used to predict nausea and then compared to patient reported outcomes using the Rotterdam Symptom Check List and medical records. Results: We show that the pathways involved in the glutathione recycling are stable for at least 48 h and that the test was able to correctly classify the risk of nausea for 89.1 % of the patients. The overall incidence of nausea was 21.9 % while women had an incidence of 29.6 %. Conclusions: This might be the first objective test to predict delayed nausea for cancer patients receiving highly emetogenic chemotherapy. We believe that this assay could better guide clinicians in their efforts to provide optimal patient-oriented care.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84991087256&origin=inward; http://dx.doi.org/10.1007/s00520-016-3442-5; http://www.ncbi.nlm.nih.gov/pubmed/27734152; http://link.springer.com/10.1007/s00520-016-3442-5; https://dx.doi.org/10.1007/s00520-016-3442-5; https://link.springer.com/article/10.1007/s00520-016-3442-5
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know